Navigation Links
Cumberland Pharmaceuticals Appoints Lee Product Director
Date:1/13/2009

NASHVILLE, Tenn., Jan. 13 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. is pleased to announce the appointment of Barry Lee as Product Director. In this role, Mr. Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for the company.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090113/CLTU094 )

"We are extremely pleased to welcome Mr. Lee to Cumberland's management team," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "As we work to continue to grow the company, we believe Barry's extensive experience and solid track record of success will be extremely valuable in helping Cumberland deliver promising new products to patients who can benefit."

Mr. Lee joins Cumberland from Bayer Healthcare Pharmaceuticals where he held a variety of sales and marketing positions during his 24-year tenure. In addition to leading sales training and development efforts, he oversaw the launch of the company's Yasmin(R) product, which was one of the most successful industry launches of its time, reaching $92 million in net sales its first year on the market. Under his leadership, the product grew to $320 million in net sales over a four-year period. Mr. Lee is a graduate of Texas A & M University.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets branded, prescription products for targeted physician segments, including hospital acute care and gastroenterology. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Cumberland Pharmaceuticals web site at www.cumberlandpharma.com.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
2. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
3. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
4. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
5. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
6. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
7. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
8. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
9. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
10. AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
11. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):